Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Monica Aparici Virgili (Sant Feliu de Llobregat, Spain), Gema Tarrasón, Irene Jover, Carla Carcasona, Joan Antoni Fernández-Blanco, Peter Eichhorn, Amadeu Gavaldà, Jorge De Alba, Richard Roberts, Montserrat Miralpeix, Mònica Aparici. Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough. Eur Respir J 2015; 46: Suppl. 59, 3948

Member's Comments

No comment yet.

Related content which might interest you: The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351) Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8 Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Abediterol has higher bronchodilatory potency than other long-acting beta2-receptor agonists in a guinea pig model Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014